MedPath

Comparative Evaluation of LaxaPlus Barij® and Polyethylene Glycol in Pediatric Functional Constipation

A randomized clinical trial compared the effectiveness of LaxaPlus Barij® and polyethylene glycol (4000) in treating functional constipation in children aged 2-15 years. The study found both treatments effective, with LaxaPlus Barij® showing a higher frequency of bowel movements and greater reduction in pain intensity and abdominal pain after 8 weeks of intervention.

Objective

This study aimed to compare the effectiveness of LaxaPlus Barij® and polyethylene glycol (4000) in treating functional constipation in children aged 2-15 years.

Methods

A randomized clinical trial was conducted with 60 children suffering from functional constipation, divided into two groups. One group received LaxaPlus Barij®, and the other received polyethylene glycol (4000) for 8 weeks. Data analysis was performed using SPSS software, with a significance level of <0.05.

Findings

The study found no significant difference in demographic characteristics between the two groups. Both treatments significantly improved stool consistency and the number of bowel movements. However, the LaxaPlus Barij® group showed a higher frequency of bowel movements and greater reduction in pain intensity and abdominal pain compared to the polyethylene glycol group.

Conclusion

Both LaxaPlus Barij® and polyethylene glycol (4000) are effective in treating functional constipation in children. LaxaPlus Barij® was more effective in increasing the frequency of bowel movements and reducing pain intensity and abdominal pain after 8 weeks of treatment. However, there was no significant difference in satisfaction levels between the two groups.

Keywords

Child, constipation, LaxaPlus Barij®, polyethylene glycol
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Ziziphus Jujube Syrup Shows Promise in Treating Pediatric Functional Constipation

A recent study compared the effectiveness of Ziziphus jujube syrup with polyethylene glycol (PEG) in treating functional constipation in children, finding that Ziziphus jujube syrup may offer a better therapeutic response and fewer side effects.

ExeGi Pharma Reports Positive Topline Results in EXE-346 PROF Phase 1b Study

ExeGi Pharma LLC announced positive topline results from the Phase 1b portion of its PROF study, demonstrating the safety and efficacy of EXE-346 in reducing excessive stool frequency and nighttime awakenings in patients with ileal pouch-anal anastomosis.

Livdelzi Demonstrates Sustained Efficacy and Long-Term Safety in Primary Biliary Cholangitis Treatment

After 2.5 years of Livdelzi (seladelpar) treatment, 81% of adults with primary biliary cholangitis (PBC) showed meaningful reductions in liver damage markers in the Phase 3 ASSURE trial.
Livdelzi significantly reduced blood levels of alkaline phosphatase (ALP), a key liver damage marker, with 41% of patients achieving normalization of ALP levels.

Linaclotide Shows Promise for Functional Constipation in Children with Neurodevelopmental Disorders

A new analysis indicates that linaclotide (Linzess) is effective in relieving functional constipation in children with neurodevelopmental disorders.
The study found that linaclotide's benefits in this specific population mirrored those observed in the broader pediatric functional constipation trial.

Erector Spinae Plane Block vs. Serratus Anterior Plane Block for Post-LSG Analgesia: A Randomized Trial

A randomized clinical trial is underway to compare the efficacy of Erector Spinae Plane Block (ESB) versus Serratus Anterior Plane Block (SAPB) for pain management after Laparoscopic Sleeve Gastrectomy (LSG).
The study aims to assess the quality of recovery at 24 hours postoperatively using the QoR-15 score as the primary outcome measure.

Clinical Trial Shows Promise for Maralixibat in Treating ALGS-Related Cholestatic Pruritus

A phase IIb clinical trial, ICONIC, evaluated the safety and efficacy of maralixibat in children with Alagille Syndrome (ALGS), showing significant improvements in serum bile acid (sBA) levels and pruritus severity. The study, involving 31 patients aged 1 to 18 years, demonstrated maralixibat's potential as a treatment for cholestatic pruritus in ALGS patients, with notable reductions in sBA and improvements in quality of life measures.

Cholecalciferol and Silymarin Combination Shows Promise in Alleviating BPH-Related LUTS

A study reveals that combined cholecalciferol and silymarin significantly improve lower urinary tract symptoms (LUTS) in benign prostatic hyperplasia (BPH) patients with vitamin D deficiency.
Silymarin alone notably reduces IPSS, irritation, obstruction, and post-void residual volume in BPH patients with sufficient vitamin D levels.

Novel Biologic Mesh Shows Promise in Laparoscopic Inguinal Hernia Repair

A novel non-crosslinked composite extracellular matrix (UBM/SIS) demonstrates comparable effectiveness to lightweight synthetic mesh in laparoscopic inguinal hernia repair (LIHR).
The study found no significant difference in hernia repair effectiveness between the UBM/SIS graft and synthetic mesh groups after a four-year follow-up period.

Double-Blind Trial Shows Comparable Efficacy in Treatment and Control Groups for Gastric Symptoms

A recent double-blind, non-inferiority, randomized controlled trial evaluated the efficacy of a treatment for various gastric symptoms, comparing it against a control group. The study found no statistically significant differences in clinical effective rates, symptom relief, and disappearance rates between the two groups, indicating comparable efficacy.

Relyvrio Shows Extended Survival Benefit in ALS Patients: PRO-ACT Database Analysis

Post-hoc analysis using the PRO-ACT database suggests Relyvrio (sodium phenylbutyrate and taurursodiol) extends median overall survival by 10.39 months in ALS patients compared to treatment-naïve controls.
The study addresses limitations of the CENTAUR trial, where placebo-to-active crossover may have underestimated Relyvrio's survival benefit in intent-to-treat analysis.

Reference News

[1]
Comparative Evaluation between the LaxaPlus Barij® and ...
ncbi.nlm.nih.gov · May 25, 2022

A study comparing LaxaPlus Barij® and polyethylene glycol (4000) for pediatric functional constipation found both effect...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy